Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer

J Clin Oncol. 2018 Mar 10;36(8):825-826. doi: 10.1200/JCO.2017.75.9829. Epub 2018 Jan 26.

Authors

Miki Horiguchi¹, Hajime Uno¹, Lee-Jen Wei¹

Affiliation

¹ Miki Horiguchi, Kitasato University School of Pharmacy, Tokyo, Japan; Hajime Uno, Dana-Farber Cancer Institute, Boston, MA; and Lee-Jen Wei, Harvard University, Boston, MA.

PMID: 29373099
DOI: 10.1200/JCO.2017.75.9829

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Male
Prostatic Neoplasms, Castration-Resistant*
Taxoids
Treatment Outcome

Substances

Taxoids
cabazitaxel